SynTheAll Pharmaceuticals Selects Linde Cryogenic Technology For Plant Expansion
The Linde Group recently announced an agreement to install a CRYOHEAT system at SynTheAll Pharmaceuticals, a wholly owned subsidiary of WuXi PharmaTech in Shanghai. WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States. CRYOHEAT is specifically designed to provide both the cooling and heating needs of process reaction vessels with a single unit. The custom system is suitable for existing plant structures and for new builds. Under the terms of the contract, Linde will also supply engineering services, maintenance support and associated bulk gases.
"We envisage good global demand for our cryogenic technology", said Joe Eschbach, Head of Marketing Chemicals and Energy with the Gases Division of The Linde Group. "Our intimate knowledge of the industry, the ability of our engineers to understand key customer issues and Linde's ability to provide custom solutions will drive future growth for us".
"The installation of Linde's CRYOHEAT®, an important part of our expansion plan, greatly enhances our manufacturing service capability. It enables us to deploy a complete turnkey solution from an advanced cryogenic system to gas and engineering services. Linde engineers also have excellent knowledge and a good understanding of our needs," said Dr. Eric Gu, Vice President of Manufacturing of WuXi PharmaTech.
Safer and more reliable than manual systems, Linde automated temperature control systems can significantly minimize maintenance and plant down time. They also offer increased accuracy in temperature control thereby improving efficiency, reducing energy consumption and preventing recurring operational issues such as ice formation. As a result, product yield and plant production capacity are greatly improved.
About The Linde Group
The Linde Group is a world leading gases and engineering company with more than 50,000 employees working in over 100 countries worldwide. In the 2007 financial year it achieved sales of EUR 12.3 billion. The strategy of The Linde Group is geared towards earnings-based and sustainable growth and focuses on the expansion of its international business with forward-looking products and services.
Linde acts responsibly towards its shareholders, business partners, employees, society and the environment – in every one of its business areas, regions and locations across the globe. Linde is committed to technologies and products that unite the goals of customer value and sustainable development. For more information, see The Linde Group web site at www. linde.com
For more information, see The Linde Group web site at www.linde.com
SOURCE: The Linde Group